Quick Answer
NEKTAR THERAPEUTICS reported Revenue (ASC 606) of $55.23 million for fiscal year 2025.
NEKTAR THERAPEUTICS Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $55.23M | -43.9% |
| 2024 | $98.43M | +9.2% |
| 2023 | $90.12M | -2.1% |
| 2022 | $92.06M | -9.7% |
| 2021 | $101.91M | -33.4% |
| 2020 | $152.91M | +33.4% |
| 2019 | $114.62M | -90.4% |
| 2018 | $1.19B | +287.8% |
| 2017 | $307.71M | +86.0% |
| 2016 | $165.44M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.79M | -51.1% | +5.5% |
| June 30, 2025 | $11.18M | -52.4% | +6.8% |
| March 31, 2025 | $10.46M | -51.7% | -56.6% |
| September 30, 2024 | $24.12M | -0.1% | +2.7% |
| June 30, 2024 | $23.49M | +14.6% | +8.5% |
| March 31, 2024 | $21.64M | +0.2% | -10.4% |
| September 30, 2023 | $24.14M | +2.2% | +17.8% |
| June 30, 2023 | $20.50M | -5.0% | -5.1% |
- NEKTAR THERAPEUTICS showed a decrease of -43.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, NEKTAR THERAPEUTICS’s revenue (asc 606) has declined by 66.6% (from $165.44 million to $55.23 million).
- The most recent figure is from NEKTAR THERAPEUTICS’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: